RET fusion-positive NSCLC has not benefited greatly from chemotherapy (8) or immune checkpoint inhibitors (ICIs) (9) although they have been widely used in patients with driver gene-negative NSCLC and achieved breakthrough progress. This evidence concerns the gene RET and non-small cell lung carcinoma.